Geron Corp. (NASDAQ:GERN)’s share price traded down 1.5% during mid-day trading on Monday . The company traded as low as $2.64 and last traded at $2.66, with a volume of 437,506 shares traded. The stock had previously closed at $2.70.

A number of equities analysts recently issued reports on the company. FBR & Co restated a “buy” rating on shares of Geron Corp. in a report on Sunday, May 8th. Zacks Investment Research raised Geron Corp. from a “hold” rating to a “strong-buy” rating and set a $3.00 target price for the company in a research report on Friday, August 5th. Finally, BTIG Research started coverage on Geron Corp. in a research report on Friday, August 19th. They issued a “neutral” rating for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $6.20.

The stock has a market capitalization of $426.49 million and a PE ratio of 335.00. The stock’s 50 day moving average price is $2.70 and its 200-day moving average price is $2.81.

Geron Corp. (NASDAQ:GERN) last posted its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.02. The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.38 million. During the same period in the prior year, the company posted ($0.06) EPS. The firm’s quarterly revenue was down 15.9% compared to the same quarter last year. Equities analysts forecast that Geron Corp. will post ($0.23) EPS for the current year.

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.